Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients.
about
Older patients with myeloma derive similar benefit from autologous transplantation.Autologous Hematopoietic Stem Cell Transplantation-10 Years of Data From a Developing CountryUse of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: impact on stem cell harvesting and engraftment.Multiple myeloma in the older adult: better prospects, more challenges.Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma.Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma.Impact of informative censoring on the Kaplan-Meier estimate of progression-free survival in phase II clinical trialsBone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1α levels in patients with MGUS.High-dose therapy and autologous stem cell transplant in older adults with multiple myeloma.Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted?Autologous transplantation in elderly patients with multiple myeloma: are we asking the right questions?Mini-Midi-Maxi? How to harness the graft-versus-myeloma effect and target molecular remission after allogeneic stem cell transplantation.Melphalan: old and new uses of a still master drug for multiple myeloma.Poor outcomes for IgD multiple myeloma patients following high-dose melphalan and autologous stem cell transplantation: a single center experience.Bortezomib in the front-line treatment of multiple myeloma.Improving stem cell mobilization strategies: future directions.Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens.Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis.Early Prognostic Value of Monitoring Serum Free Light Chain in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.Stem cell transplantation for multiple myelomaAutologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma without Cryopreservation.Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo OsseoBortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma.Predicting durable remissions following thalidomide therapy for relapsed myeloma.Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: a retrospective study.Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin's lymphoma.Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation.Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study.Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma.High-dose chemotherapy with autologous stem cell transplantation for multiple myeloma: what predicts the outcome? Experience from a developing country.
P2860
Q30370038-2FFB5D97-BC59-4713-B135-E1E7F9B90BC3Q30962747-DD220695-1F18-41F4-9B84-416A058D24E0Q33376918-4A954C6B-560F-48E3-A4A2-F9FCCF556F8FQ34031129-15502BAD-FB87-4081-A5FF-0A41189D18D1Q34115051-6106A843-4A92-46D0-9A46-C2562DB0CC20Q34166574-C0CF75A3-DD5A-4C8C-8D45-968D057520C4Q34172071-DE14B844-0547-405B-882E-E917D1A36B3DQ35623636-D6C5312E-81F3-4DAF-A9B9-8A5078AC55B2Q35920754-042A91B9-356D-4AFE-B0D8-D9CC2F533715Q36484561-0C5E8534-FCBC-406C-9D76-73A3AF7CBF24Q36585737-7425E742-3D7D-4653-9AD4-871583C6AE43Q36849339-AFFDF3AC-A5E6-4C9D-B8CE-85B9FB477D93Q36916889-136939D2-D18A-4E85-A31E-C32B69F4E18AQ36966074-F1FC0503-2F57-401A-8F22-FE41677BB752Q37202761-C2EC8003-E2C1-450F-BC5C-A196FB1864D7Q37367235-8FA6F567-43A8-43C8-A15E-6E2677930F93Q37827058-1EAA4676-6EE4-4F0F-95AE-BD9610E0B255Q39378263-7537693D-89AF-4073-890B-7E85A7133575Q40368431-7B8EFB3D-A718-4E41-B4B7-871A982F04F2Q41819684-E049C8CC-6ADA-4232-B69B-2D4AD02D469FQ42184785-E71041CE-28E9-4247-80DC-3519C98AA114Q42592824-FFEF7667-9534-486B-A0FA-1811F494F188Q43225847-9A10EE27-3144-41E3-B000-CB6B1C5F80BAQ44763325-E9E9A977-24C5-4DA8-9050-F39C346248F0Q45287020-10DC0C01-A411-4586-A71F-ADD646E443ABQ46208758-41A17C7B-A5D6-4E68-B2BE-0E0EB64A5D99Q46469277-663A3214-905A-42ED-894B-C69757CA244AQ51741922-87C065AC-B175-4965-B129-04E8FDABBBA7Q52868558-3E796C4A-215A-4AD7-97B4-14B5B4808E1CQ53206127-4548077A-6F7F-46F0-99BD-46CCC24F32FE
P2860
Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Predictive factors for surviva ...... re experience in 211 patients.
@en
Predictive factors for surviva ...... re experience in 211 patients.
@nl
type
label
Predictive factors for surviva ...... re experience in 211 patients.
@en
Predictive factors for surviva ...... re experience in 211 patients.
@nl
prefLabel
Predictive factors for surviva ...... re experience in 211 patients.
@en
Predictive factors for surviva ...... re experience in 211 patients.
@nl
P2093
P2860
P356
P1476
Predictive factors for surviva ...... re experience in 211 patients.
@en
P2093
Apperley JF
Olavarria E
P2860
P2888
P304
P356
10.1038/SJ.BMT.1705307
P407
P577
2006-04-01T00:00:00Z
P5875
P6179
1032025537